Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2017-03-31 Capital/Financing Update
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Proposed Placing to raise up to approx. £20.0m
Capital/Financing Update Classification · 100% confidence The document is an official announcement from MaxCyte, Inc. regarding a 'Proposed Placing' to raise capital through the issuance of new shares. It details the purpose of the funds, the accelerated bookbuilding process, and the conditional nature of the placing. This falls squarely under the definition of a Capital/Financing Update (CAP), as it describes a specific fundraising activity and changes to the company's capital structure.
2017-03-31 English
Full Year Results
Earnings Release Classification · 95% confidence The document is an official announcement from MaxCyte, Inc. regarding its full-year audited results for the year ended 31 December 2016. It contains financial highlights, operational updates, and a joint review from the CEO and Chairman. While it provides a comprehensive summary of the year's performance, it is structured as an 'Earnings Release' (ER) announcement, as indicated by the 'RNS Number' header, the date of release, and the summary-style presentation of highlights followed by management commentary, which is typical for an initial earnings announcement rather than the full, multi-hundred-page 10-K or Annual Report document. FY 2016
2017-03-20 English
CRISPR THERAPEUTICS/CASEBIA COMMERCIAL LICENSE
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a commercial license agreement between MaxCyte, Inc., CRISPR Therapeutics, and Casebia Therapeutics. Since this is a corporate announcement regarding a business partnership/licensing deal and does not fit into specific categories like M&A (which usually implies a takeover or merger of entities) or other specialized financial reports, it is classified as a general regulatory filing.
2017-03-14 English
MaxCyte to Present Pre-Clinical CARMA Data at AACR
Regulatory Filings Classification · 95% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces that MaxCyte, Inc. will present pre-clinical data at an upcoming medical conference (AACR). It does not fit into specific categories like financial reports, M&A, or director dealings, and serves as a general corporate announcement regarding research progress. Therefore, it is classified as a Regulatory Filing (RNS).
2017-03-02 English
Notice of Full Year Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. titled 'Notice of Full Year Results'. It informs the market that the company will be announcing its full-year audited results on a future date (20 March 2017). Per the 'Menu vs Meal' rule, this is an announcement regarding the publication of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2017-03-01 English
MaxCyte Announces Collaboration to Advance CARMA
Regulatory Filings Classification · 100% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a strategic collaboration between MaxCyte, Inc. and Washington University in St. Louis regarding the development of the CARMA platform. As this is a general corporate announcement regarding business operations and partnerships that does not fit into specific financial reporting categories like 10-K, IR, or DIV, it falls under the RNS (Regulatory Filings) category.
2016-12-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.